Deal Tracker · Years

Emerging-market pharma deals in 2024

6 pharma deals announced in 2024 across MENA, GCC & Africa, tracked by EPT — investment, licensing & joint ventures. Most active: Tabuk Pharmaceuticals, Afreximbank, Bio-Thera Solutions & Biocon. Latest: Bio-Thera Solutions → Tabuk Pharmaceuticals (Licensing, 24 Dec 2024).

6
deals tracked
8
countries involved
$52m
disclosed value (2 deals)
33%
investment, the top deal type
  • EPT has tracked 6 emerging-market pharma deals in 2024.
  • The most common structures are investment (33%), licensing (33%) & joint ventures (17%).
  • The countries that appear most often are Saudi Arabia (3), China (2), India (2) & Egypt (1).
  • Values were disclosed for 2 of 6 deals, totalling $52m; the largest is Afreximbank → Med Aditus Pharmaceutical Kenya ($40m, 29 Nov 2024).
  • The most active companies: Tabuk Pharmaceuticals (2).

Most active companies

Tabuk Pharmaceuticals (2)

Countries involved

Saudi Arabia (3) · China (2) · India (2) · Egypt (1) · Kenya (1) · Oman (1)

Largest disclosed deals

Questions

How many emerging-market pharma deals in 2024 has EPT tracked?
6 as of 24 Dec 2024. The most recent is Bio-Thera Solutions → Tabuk Pharmaceuticals (Licensing, 24 Dec 2024).
What types of emerging-market pharma deals in 2024 are most common?
Equity / Investment: 2 (33%); Licensing: 2 (33%); Joint venture: 1 (17%); Partnership / Collaboration: 1 (17%).
Which companies are most active in emerging-market pharma deals in 2024?
Tabuk Pharmaceuticals (2 deals).
What is the largest disclosed emerging-market pharma deal in 2024?
Afreximbank → Med Aditus Pharmaceutical Kenya: $40m (Equity / Investment, 29 Nov 2024); Immuneel Therapeutics → Taiba Healthcare: $12m (Equity / Investment, 30 Jul 2024). Values are as announced by the parties.
Which countries appear most in emerging-market pharma deals in 2024?
Saudi Arabia (3), China (2), India (2), Egypt (1), Kenya (1), Oman (1) — counting where the parties are based and the markets the deals cover.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)